Ostia Sciences, a spinout from the University of Toronto specializing in oral and respiratory microbiome solutions, raised over CAD$1M in Seed funding and secured full intellectual property (IP) transfer from the university.
Backers were not disclosed.
With full IP ownership, Ostia can independently advance research and development, solidifying its position as a leader in the emerging “Bugs to Drugs” biotherapeutic field.
The company intends to use the funds to further research and clinical trials, supporting the development of its SALI-10 probiotic, based on its phosphorylated lantibiotic technology, which is ready for clinical trials targeting respiratory and oral diseases in early 2025
Led by CEO Dr. Abdelahhad Barbour, Ostia Sciences is a biotech company specializing in the development of oral probiotics and biotherapeutics. Through research and a commitment to microbiome science, it is dedicated to improving global health outcomes with biotherapeutic solutions.
The company aims to close the round with an additional $700K by December 2024.
FinSMEs
02/10/2024